NCT03698617 is a Phase 2 clinical trial of HSK3486 in Induction of General Anaesthesia, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd.

Who is sponsoring NCT03698617?

NCT03698617 is sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd.

What drugs are being tested in NCT03698617?

Interventions in NCT03698617: HSK3486, Propofol.

What condition does NCT03698617 study?

NCT03698617 studies Induction of General Anaesthesia.

Is NCT03698617 still recruiting?

NCT03698617 is currently completed. Last updated 9 October 2018.

Last reviewed 2018-10-09 · How we verify

NCT03698617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486

Completed Phase 2 Last updated 9 October 2018

What this trial tests

Phase 2 trial testing HSK3486 in Induction of General Anaesthesia in 114 participants. Completed in 18 July 2018.

Timeline

6 December 2016

Primary endpoint
29 June 2018

18 July 2018

Quick facts

Lead sponsor	Sichuan Haisco Pharmaceutical Group Co., Ltd
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	114
Start date	6 December 2016
Primary completion	29 June 2018
Estimated completion	18 July 2018
Sites	1 location across China

Drugs / interventions tested

HSK3486 — full drug profile →
Propofol (Propofol) — full drug profile →

Conditions studied

Induction of General Anaesthesia — all drugs for Induction of General Anaesthesia →

Sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Induction of General Anaesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase IIa, open-label, propofol-controlled ,dose-escalation, multi-center Study to evaluate the tolerance, efficacy and safety of HSK3486 for induction of general anesthesia in elective surgery patients.This study is consisted of two cohorts, dose-escalation and dose-expansion cohorts. The doses in dose- expansion cohort were selected from dose-escalation results.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial.
Liu Y, Yu X, Zhu D, Zeng J, et al · · 2022 · cited 58× · PMID 34924506 · DOI 10.1097/cm9.0000000000001912
Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly.
Li X, Yang D, Li Q, Wang H, et al · · 2021 · cited 55× · PMID 34512361 · DOI 10.3389/fphar.2021.735700
Efficacy and safety of ciprofol versus propofol for the induction of anesthesia in adult patients: a multicenter phase 2a clinical trial.
Zhu Q, Luo Z, Wang X, Wang D, et al · · 2023 · cited 32× · PMID 36680620 · DOI 10.1007/s11096-022-01529-x
Protective effects of combined treatment with ciprofol and mild therapeutic hypothermia during cerebral ischemia-reperfusion injury.
Wang YC, Wu MJ, Zhou SL, Li ZH. · · 2023 · cited 7× · PMID 36793629 · DOI 10.12998/wjcc.v11.i3.487
Effects of Cipepofol on Cardiac Depolarization and Repolarization in Healthy Subjects: A Single-Center, Randomized, Placebo and Positive-Controlled Thorough QT Study.
Kleiman R, Rudo T, Daley W, Hu M, et al · · 2026 · PMID 41858914 · DOI 10.2147/dddt.s565051

Verify or expand the search:

Other trials of HSK3486

Trials testing the same drug.

NCT06795204 — Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT) · Phase 1 · completed
NCT05486416 — Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery · Phase 3 · completed
NCT05614544 — Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System D · Phase 1 · completed
NCT07404306 — Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users · Phase 1 · completed
NCT05478174 — Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia · Phase 3 · completed

Other Sichuan Haisco Pharmaceutical Group Co., Ltd trials

Trials by the same sponsor.

NCT04540016 — Mass Balance and Biotransformation of [14C]HSK7653 in Human · Phase 1 · completed
NCT04564872 — HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus · Phase 3 · completed
NCT04556851 — HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise · Phase 3 · completed
NCT04110886 — Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers · Phase 1 · completed
NCT04595916 — Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03698617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Haisco Pharmaceutical Group Co., Ltd
Last refreshed: 9 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03698617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing